Japanese Pharmacology & Therapeutics (JPT)
Vol. 46 Suppl. 2 2018
■REVIEW Countermeasures for "Clinical Trials Act"
To Operate the Clinical Trials Act Properly
—Consideration of Collaborative Clinical Research
Y. Noda, et al
Jpn Pharmacol Ther 2018 46(s2) s66-76
■ SYMPOSIUM
Consideration from Practical Example of Clinical Trial by Medical Equipment
～Effects of Extracorporeal Shockwave Therapy on Digital Ulcer of Systemic Sclerosis～
T. Ishii
Jpn Pharmacol Ther 2018 46(s2) s78-9
Drug Safety Assessment Utilizing Electronic Medical Information
Y. Uyama
Jpn Pharmacol Ther 2018 46(s2) s80-1
Basic Principles on the Reliability of Patients Registry Data When Utilized in the Application for Marketing Authorization and Post-Marketing Surveillance of Medical Products (Draft)
T. Shibata
Jpn Pharmacol Ther 2018 46(s2) s82-4
Attempt at Data-sharing in the Activities of Public Private Partnerships by the Japanese Society of Neuropsychopharmacology
Y. Morio
Jpn Pharmacol Ther 2018 46(s2) s85-6
The Present Conditions and Problems of Clinical Trial Office Function
N. Kondo, et al
Jpn Pharmacol Ther 2018 46(s2) s87-9
Report on the Role and Future Task of a Clinical Research Office in an Ethical Review Committee of a Medical Institution Certified by the Certification Ethical Review Committee Project, AMED
Y. Ishii
Jpn Pharmacol Ther 2018 46(s2) s90-1
■ ORIGINAL ARTICLE
Knowledge of Physicians and Healthcare Professionals and Their Need for Support Systems of Advanced and Investigational Medical Care in Oncology
T. Takayama, et al
Jpn Pharmacol Ther 2018 46(s2) s101-13
■ BRIEF REPORT
Analysis of the Status of Investigator-Initiated Clinical Trials in Japan and Consideration of Its Changing Roles
Y. Sakakibara, et al
Jpn Pharmacol Ther 2018 46(s2) s114-20